Evotec opens the week with sector pressure, shares trade near recent lows

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 14:38.

Evotec (DE0005664809) starts the new week with a subdued share price in Xetra trading. The biotech group remains under visible pressure after a pronounced one-year drawdown within the SDAX and TecDAX segments, according to current German market data.Finanznachrichten price overview for Evotec

Where Evotec shares stand

On the German market, Evotec shares recently traded at around 4.91 euros, implying a market capitalization near 910 million euros per late June figures.MarketBeat data on Evotec shares The 52-week range between roughly 5.06 and 21.69 euros points to a marked loss of market value over the past year.MarketBeat range and market cap figures

Biotech peer and index backdrop

Evotec belongs to the biotechnology sector, trading in the Prime Standard segment and represented in the SDAX and TecDAX indices on the Frankfurt exchange.Finanznachrichten classification of Evotec Sector peers in Germany include MorphoSys and BioNTech, which likewise face cyclical swings tied to pipeline news and funding conditions.

The product behind the stock

Evotec’s core business centers on drug discovery and development services for pharmaceutical and biotechnology partners worldwide. The company runs integrated discovery platforms, offering hit identification, preclinical development and translational services under multi-year collaboration agreements with large pharma groups.

Where the shares trade today

The Evotec shares (DE0005664809) most recently traded on Xetra at about 4.91 euros, based on late-June 2026 price data.

This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. Values and dates are based on sources cited and may change over time.